Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-NP
- Development stage
- Discontinued
- Lead developer
- Barinthus Biotherapeutics
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
MVA-NP is a recombinant viral vector vaccine candidate that utilizes the Modified Vaccinia Ankara (MVA) platform to express the highly conserved internal nucleoprotein (NP) of the influenza A virus. This construct is designed to induce T-cell responses, aiming for broad protection against influenza. While MVA-NP itself is a specific construct, it is predominantly developed and studied in combination with Matrix protein 1 (M1) as the vaccine candidate MVA-NP+M1. MVA-NP+M1 has been investigated in clinical trials for its ability to boost cross-reactive T-cell responses against influenza A viruses, particularly in older adults, with the goal of circumventing immunosenescence that impairs routine influenza vaccination.
- Other names
- Modified Vaccinia Ankara expressing Nucleoprotein
02
Targets
NP (Taï Forest ebolavirus nucleoprotein)
Beyond the preview
Go deeper on MVA-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-NP.